(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of 120.68% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.41%.
Meiragtx Holdings's revenue in 2025 is $33,279,000.On average, 2 Wall Street analysts forecast MGTX's revenue for 2025 to be $10,009,845,576, with the lowest MGTX revenue forecast at $2,624,292,270, and the highest MGTX revenue forecast at $17,395,398,882. On average, 2 Wall Street analysts forecast MGTX's revenue for 2026 to be $19,105,762,443, with the lowest MGTX revenue forecast at $15,045,521,789, and the highest MGTX revenue forecast at $23,166,003,098.
In 2027, MGTX is forecast to generate $15,353,056,039 in revenue, with the lowest revenue forecast at $15,353,056,039 and the highest revenue forecast at $15,353,056,039.